We used the ELEN index ( an algorithm to predict elevated sputum eosinophils ) or baseline fraction of exhaled nitric oxide to stratify patients by eosinophilic status , and with an interactive web-voice response system randomly assigned eosinophilic individuals in a @:@:@:@ ratio to receive placebo , @ mg benralizumab , @ mg benralizumab , or @ mg benralizumab , and non-eosinophilic individuals in a @:@ ratio to receive placebo or @ mg benralizumab .